Smart science to improve lives™
Banner image for japan country page

Japan

Croda Japan was originally formed as a 50:50 partnership of Croda International in 1966, and in 1989 became wholly owned by Croda. One of the pioneering foreign-owned companies to establish its own manufacturing site in Japan, our site in Shiga also developed a process that produces products of extremely high levels of purity, primarily for Personal Care and Health Care. In 2013, it was the second manufacturing site in Japan to be awarded the EFfCI (European Federation for Cosmetic Ingredients) GMP certification and in 2017 was the first in Japan to be awarded the EXCIPACT certificate. Producing a wide range of natural-based specialties from materials such as vegetable oils and lanolins, we also manufacture esters and wax.

The working environment is a good balance of Japanese culture with the dynamism of a global company. Our team enjoys the Croda culture of “safety first, people first”, with employee wellbeing a priority. 


Croda Japan KK

Shinjuku Park Tower 11th Floor
3-7-1, Nishi-shinjuku, Shinjuku-ku
Tokyo, Japan 163-1011
Tel: +81(0) 3 6258-1910
Fax: +81(0) 3 5322-2122


Shiga Manufacturing Site

Gokasho Hiyoshi-cho
Higashiomi-shi
Shiga, Japan, 529-1403
Tel: +81 (0)748 48 3701
Fax: +81 (0)748 45 5721 

About Croda Japan. クローダジャパン会社概要

Our Innovation Centre at global headquarters Cowick Hall

Contact us

Whether you’re a customer, potential partner, job seeker or investor, please use our contact us form for your enquiry.

Croda Formulator at work in labs

Where we operate

Every day our global team, across 37 countries, work together to inspire our customers.

Further reading

Sustainability expert Aris Vrettos joins Croda

The new position will see the sustainability expert challenge Croda to stretch its already industry-leading sustainability ambitions and commitments and support Croda’s business sectors in further...

Read more
Laboratory work

UK Government to support expansion of Croda's lipid systems manufacturing facility

31 March 2022: This investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines.

Read more

Sustainability success with EcoVadis rating

24 May 2022: Sustainability success after retaining its position within the top 1% of companies assessed by EcoVadis

Read more

Launch of Croda Pharma

23 May 2022: Our Health Care division becomes Croda Pharma

Read more